Literature DB >> 20127285

Sphingosine-1-phosphate receptors: zooming in on ligand-induced intracellular trafficking and its functional implications.

Dennis Verzijl1, Stephan L M Peters, Astrid E Alewijnse.   

Abstract

Regulatory processes including receptor phosphorylation and intracellular trafficking, also referred to as receptor internalization, are important processes to terminate G protein-coupled receptor (GPCR) signaling. Compelling evidence now indicates that internalization of a receptor is not necessarily the endpoint of signaling, but can also be the beginning of the activation of intracellular signaling pathways. Sphingosine-1-phosphate (S1P) receptors, which are activated by the endogenous phospholipid S1P, belong to the family of GPCRs. Interestingly, there is evidence indicating differential intracellular trafficking of one of the S1P receptor subtypes, the S1P1 receptor, upon agonist activation by either S1P or the synthetic agonist FTY720-P. Moreover, the differential effect of FTY720-P on S1P1 receptor regulation has been suggested to be the mechanism of action of this drug, which is now in Phase III clinical trials for the treatment of multiple sclerosis. It is thus of importance to get a good insight into the regulation of S1P receptors. This review therefore gives a detailed overview about the current state of knowledge on S1P receptor internalization and its functional implications, including some data on nuclear signaling of S1P receptors.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20127285     DOI: 10.1007/s10059-010-0041-z

Source DB:  PubMed          Journal:  Mol Cells        ISSN: 1016-8478            Impact factor:   5.034


  15 in total

1.  Intracellular GPCRs Play Key Roles in Synaptic Plasticity.

Authors:  Yuh-Jiin I Jong; Steven K Harmon; Karen L O'Malley
Journal:  ACS Chem Neurosci       Date:  2018-02-16       Impact factor: 4.418

Review 2.  GPCR signalling from within the cell.

Authors:  Yuh-Jiin I Jong; Steven K Harmon; Karen L O'Malley
Journal:  Br J Pharmacol       Date:  2017-10-03       Impact factor: 8.739

3.  Benzofuran Derivatives as Potent, Orally Active S1P1 Receptor Agonists: A Preclinical Lead Molecule for MS.

Authors:  Ashis K Saha; Xiang Yu; Jian Lin; Mercedes Lobera; Anurag Sharadendu; Srinivas Chereku; Nili Schutz; Dalia Segal; Yael Marantz; Dilara McCauley; Scot Middleton; Jerry Siu; Roland W Bürli; Janet Buys; Michelle Horner; Kevin Salyers; Michael Schrag; Hugo M Vargas; Yang Xu; Michele McElvain; Han Xu
Journal:  ACS Med Chem Lett       Date:  2010-11-09       Impact factor: 4.345

4.  FTY720 normalizes hyperglycemia by stimulating β-cell in vivo regeneration in db/db mice through regulation of cyclin D3 and p57(KIP2).

Authors:  Zhengshan Zhao; Jinwoo Choi; Chunying Zhao; Zhongmin Alex Ma
Journal:  J Biol Chem       Date:  2011-12-22       Impact factor: 5.157

5.  Osteoblast regulation via ligand-activated nuclear trafficking of the oxytocin receptor.

Authors:  Adriana Di Benedetto; Li Sun; Carlo G Zambonin; Roberto Tamma; Beatrice Nico; Cosima D Calvano; Graziana Colaianni; Yaoting Ji; Giorgio Mori; Maria Grano; Ping Lu; Silvia Colucci; Tony Yuen; Maria I New; Alberta Zallone; Mone Zaidi
Journal:  Proc Natl Acad Sci U S A       Date:  2014-11-05       Impact factor: 11.205

6.  FTY720 (fingolimod) increases vascular tone and blood pressure in spontaneously hypertensive rats via inhibition of sphingosine kinase.

Authors:  Léon J A Spijkers; Astrid E Alewijnse; Stephan L M Peters
Journal:  Br J Pharmacol       Date:  2012-06       Impact factor: 8.739

7.  The development and maintenance of paclitaxel-induced neuropathic pain require activation of the sphingosine 1-phosphate receptor subtype 1.

Authors:  Kali Janes; Joshua W Little; Chao Li; Leesa Bryant; Collin Chen; Zhoumou Chen; Krzysztof Kamocki; Timothy Doyle; Ashley Snider; Emanuela Esposito; Salvatore Cuzzocrea; Erhard Bieberich; Lina Obeid; Irina Petrache; Grant Nicol; William L Neumann; Daniela Salvemini
Journal:  J Biol Chem       Date:  2014-07-25       Impact factor: 5.157

8.  A sphingosine kinase form 2 knockout sensitizes mouse myocardium to ischemia/reoxygenation injury and diminishes responsiveness to ischemic preconditioning.

Authors:  Donald A Vessey; Luyi Li; Zhu-Qiu Jin; Michael Kelley; Norman Honbo; Jianqing Zhang; Joel S Karliner
Journal:  Oxid Med Cell Longev       Date:  2011-04-18       Impact factor: 6.543

9.  FTY720 postconditions isolated perfused heart by a mechanism independent of sphingosine kinase 2 and different from S1P or ischemic postconditioning.

Authors:  Donald A Vessey; Luyi Li; Isabella Imhof; Norman Honbo; Joel S Karliner
Journal:  Med Sci Monit Basic Res       Date:  2013-04-09

10.  Targeting the S1P/S1PR1 axis mitigates cancer-induced bone pain and neuroinflammation.

Authors:  Shaness A Grenald; Timothy M Doyle; Hong Zhang; Lauren M Slosky; Zhoumou Chen; Tally M Largent-Milnes; Sarah Spiegel; Todd W Vanderah; Daniela Salvemini
Journal:  Pain       Date:  2017-09       Impact factor: 7.926

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.